Scholars Central

Short communicationPublished 2013

The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia

Authors: Katerina Skrivanova, Marcela Bendova, Ladislav Dusek, Daniela Zackova, Zdenek Racil, Jiri Mayer

Journal of Blood Disorders & Transfusion

Volume 4 · Issue 6 · Pages 1–5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Purpose: The objective of this study was to evaluate the quality of life (QL) as well as the frequency and severity of depression in patients with chronic phase chronic myeloid leukemia (CP-CML) in relation to the duration of Imatinib treatment. Methods: A detailed analysis of 56 adult patients with CP CML divided into groups according to the length of Imatinib treatment was performed as follows: Group A (n=28)- patients treated for 15 months (median); and Group B (n=28)-patients treated for 50 months (median). All used questionnaires EORTC QLQ-C30 (version 2), SF 36 and BDI were localized and validated. Results: The results from the QL questionnaires found a trend in the improvement in the QL of patients treated with Imatinib for 50 months (median) compared to patients treated for 15 months (median) only. However, a statistically significant improvement in the QL of patients with longer Imatinib treatment was found only in patients without co-existing invalidity and/or rheumatic disease. Moreover, these two comorbidities increased the level of depressive symptoms in patients with CML during the early period of Imatinib therapy. Conclusion: We found a trend in the improvement in the QL of patients with CML in relation to the duration of Imatinib therapy. Statistically significant improvement in the QL of patients with longer Imatinib treatment was found in patients without co-existing invalidity and/or rheumatic disease only.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Blood Disorders & Transfusion
  • SubjectHaematology
  • BylineArticles whose byline prints “Katerina Skrivanova”
  • BylineArticles whose byline prints “Marcela Bendova”
  • BylineArticles whose byline prints “Ladislav Dusek”
  • BylineArticles whose byline prints “Daniela Zackova”
  • BylineArticles whose byline prints “Zdenek Racil”
  • BylineArticles whose byline prints “Jiri Mayer”